Acadia Pharmaceuticals Inc [NASDAQ: ACAD] slipped around -2.34 points on Wednesday, while shares priced at $21.26 at the close of the session, down -9.92%.
Acadia Pharmaceuticals Inc stock is now 28.61% up from its year-to-date (YTD) trading value. ACAD Stock saw the intraday high of $21.86 and lowest of $20.02 per share. The company’s 52-week high price is 26.65, which means current price is +58.66% above from all time high which was touched on 08/28/25.
Compared to the average trading volume of 1.89M shares, ACAD reached a trading volume of 8440646 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Acadia Pharmaceuticals Inc [ACAD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACAD shares is $29.39 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACAD stock is a recommendation set at 1.89. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Deutsche Bank have made an estimate for Acadia Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 21, 2025. While these analysts kept the previous recommendation, Deutsche Bank raised their target price to Hold. The new note on the price target was released on February 11, 2025, representing the official price target for Acadia Pharmaceuticals Inc stock. Previously, the target price had yet another drop from $23 to $20, while Guggenheim kept a Neutral rating on ACAD stock.
The Price to Book ratio for the last quarter was 4.36, with the Price to Cash per share for the same quarter was set at 4.52. Price to Free Cash Flow for ACAD in the course of the last twelve months was 19.17 with Quick ratio for the last quarter at 2.83.
How has ACAD stock performed recently?
Acadia Pharmaceuticals Inc [ACAD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.15. With this latest performance, ACAD shares dropped by -16.03% in over the last four-week period, additionally plugging by 24.25% over the last 6 months – not to mention a rise of 15.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACAD stock in for the last two-week period is set at 30.57, with the RSI for the last a single of trading hit 1.11, and the three-weeks RSI is set at 0.93 for Acadia Pharmaceuticals Inc [ACAD]. The present Moving Average for the last 50 days of trading for this stock 24.29, while it was recorded at 23.71 for the last single week of trading, and 19.92 for the last 200 days.
Acadia Pharmaceuticals Inc [ACAD]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Acadia Pharmaceuticals Inc [ACAD] shares currently have an operating margin of 8.86% and a Gross Margin at 91.97%. Acadia Pharmaceuticals Inc’s Net Margin is presently recorded at 21.80%.
Acadia Pharmaceuticals Inc (ACAD) Capital Structure & Debt Analysis
According to recent financial data for Acadia Pharmaceuticals Inc. ( ACAD), the Return on Equity (ROE) stands at 33.18%, highlighting impressive shareholder gains. The Return on Assets (ROA) is 20.77%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Acadia Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is 25.62%, showcasing its effectiveness in deploying capital for earnings.
Acadia Pharmaceuticals Inc (ACAD) Efficiency & Liquidity Metrics
Based on Acadia Pharmaceuticals Inc’s (ACAD) latest financial statements, the Debt-to-Equity Ratio is 0.07%, indicating its reliance on debt financing relative to shareholder equity.
Acadia Pharmaceuticals Inc (ACAD) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Acadia Pharmaceuticals Inc. (ACAD) effectively leverages its workforce, generating an average of $339694.19 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.91% and a Quick Ratio of 2.83%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Acadia Pharmaceuticals Inc [ACAD]
With the latest financial reports released by the company, Acadia Pharmaceuticals Inc posted 0.2/share EPS, while the average EPS was predicted by analysts to be reported at 0.14/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.06. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACAD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Acadia Pharmaceuticals Inc go to 0.23%.
Insider trade positions for Acadia Pharmaceuticals Inc [ACAD]
There are presently around $103.21%, or 103.79%% of ACAD stock, in the hands of institutional investors. The top three institutional holders of ACAD stocks are: BAKER BROS. ADVISORS LP with ownership of 42.88 million shares, which is approximately 25.9001%. VANGUARD GROUP INC, holding 13.71 million shares of the stock with an approximate value of $$222.82 million in ACAD stocks shares; and VANGUARD GROUP INC, currently with $$222.75 million in ACAD stock with ownership which is approximately 8.2799%.
